成人心脏手术患者直接口服抗凝药管理:SCA与STS联合共识声明
SCA与STS联合发布共识,针对服用直接口服抗凝药(DOACs,含Xa因子抑制剂和直接凝血酶抑制剂)的成人心脏手术患者,系统综述了术前停药、监测、桥接需求、逆转剂及术后恢复用药等文献,并结合专家共识形成推荐,以提升患者安全与结局。
要点
- 术前需根据DOAC类型和肾功能计划停药,无需常规桥接。
- 监测DOAC效果可选用特定检测,逆转剂用于紧急手术。
- 术后恢复DOAC时机需权衡出血与血栓风险。
核心结论
- 该共识为服用DOAC的成人心脏手术患者提供围术期管理推荐,旨在提高安全性和结局。
研究设计与样本
- 由SCA与STS联合制定,基于系统文献综述和专家共识形成总结声明。
主要发现
- 系统综述涵盖DOAC术前停药、监测选项、桥接需求、逆转剂及术后恢复用药等主题。
- 总结声明结合证据与专家共识,指导各领域患者管理。
临床怎么用
- 临床可参照共识声明管理服用DOAC的成人心脏手术患者围术期抗凝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Society of Cardiovascular Anesthesiologists (SCA) along with The Society of Thoracic Surgeons (STS) sought to improve the care of adult patients undergoing cardiac surgery who are taking direct oral anticoagulants (DOACs), such as factor Xa and direct thrombin inhibitors. To fulfill this, a systematic review of the literature on cessation of DOACs before cardiac surgery, options for monitoring DOACs, the need for bridging, reversal agents, and resuming the medications after surgery was performed. Additionally, an expert consensus around the management of these patients was completed. Summary statements were created using evidence and expert consensus to guide care of patients in each of these domains, with the ultimate goal to enhance patient safety and outcomes.
引用
- Budd AN, Kertai MD, Wyler von Ballmoos MC, et al. Management of Direct Oral Anticoagulants in Adult Patients Undergoing Cardiac Surgery: A Joint Consensus Statement by the Society of Cardiovascular Anesthesiologists and The Society of Thoracic Surgeons. Ann Thorac Surg. 2026. PMID: 41609547. doi:10.1016/j.athoracsur.2026.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。